GlassScriptPhysician profile
Evelyn Cordero
NPI 1003823584
$5,045.31
in general payments reported to CMS, 2019-2025
18 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $574 · 2021: $1,414 · 2022: $1,209 · 2023: $573 · 2024: $389 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,293.99 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Lilly USA, LLC | $816.71 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $787.71 | 2019-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $729.88 | 2021-2025 | |
| Novo Nordisk INC | $391.63 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.20 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $138.95 | 2019-2025 | Veozah |
| Pfizer INC. | $137.97 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $93.66 | 2019-2021 | |
| Emd Serono, INC. | $79.87 | 2022-2023 | Mavenclad |
| Amgen INC. | $70.09 | 2023-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $67.57 | 2019 | |
| Amarin Pharma, INC. | $41.56 | 2019-2020 | |
| Althera Pharmaceuticals LLC | $22.05 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.59 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17.78 | 2019 | |
| Dexcom, INC. | $17.60 | 2021 | |
| Abbott Laboratories | $14.50 | 2023 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Cordero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.